Latest News
ACON Investments, Humus Capital Partner to Acquire Biosidus
Wednesday 13 June 2018

13 June 2018 - Affiliates of Washington, US-based ACON Latin America Opportunities Fund IV, L.P., in partnership with Argentina-based private equity firm Humus Capital Partners (HCP) have acquired a majority equity interest in Argentina-based biosimilar pharmaceuticals distributor Biosidus S.A. and Biosidus Farma S.A. the company said.

Terms of the transaction were not disclosed.

ACON and HCP will continue Biosidus' international expansion strategy, building on its track record of more than 150 m doses of biosimilar pharmaceuticals produced over the last two decades.

Biosidus' product portfolio comprises some of the most successful biosimilars developed to date with a focus on the treatment of chronic renal failure, cancer, multiple sclerosis, growth hormone deficiency and osteoporosis, among others.

ACON's experience as one of the longest continuous investors in Latin America, having managed over USD 1.6bn in investments throughout the region over the last two decades, as well as HCP's proven experience, networks and reputation in Argentina.

ACON is an international private equity investment firm that manages private equity funds and special purpose partnerships that make investments in the United States and Latin America. ACON and its principals have managed approximately USD 5.3bn of capital. ACON has professionals in Washington, DC, Los Angeles, São Paulo, Mexico City, and Bogotá.

HCP invests primarily in family-owned companies across multiple sectors in Argentina, Chile and Uruguay, often as the local partner of choice for international investment firms without a dedicated presence in those countries.
Date Published: 13/06/2018
Target: Biosidus S.A. and Biosidus Farma/majority stake
Country: Argentina
Sector: Pharmaceuticals
Type: LBO
Status: Agreed
Buyer: ACON Latin America Opportunities Fund IV, Humus Capital Partners
Terms of the deal were not disclosed